The annual congress of the European Heart Rhythm Association (EHRA), a branch of the ESC, will be held April 3-5 at the Bella Center in Copenhagen, Denmark and online. Explore the scientific program.
March 31, 2022
EHRA 2022: Cutting Edge Science in Heart Rhythm Disorders
March 31, 2022 — The annual congress of the European Heart Rhythm Association (EHRA), a branch of the ESC, will be held…
Read More
COVID-19 patient
March 31, 2022
International Multi-center Study Confirms Stroke Risk in Younger Healthier COVID-19 Patients
April 1, 2022 – Over the course of the pandemic, a number of studies examined whether COVID-19 patients were at…
Read More
Study researchers
March 31, 2022
Living Near Green Areas Reduces the Risk of Suffering a Stroke by 16%
April 1, 2022 – The risk of suffering an ischemic stroke, the most common type of cerebrovascular event, is 16% less in…
Read More
Investigators from Cedars-Sinai have created an artificial intelligence-enabled tool that may make it easier to predict if a person will have a heart attack.
March 31, 2022
Artificial Intelligence Tool May Help Predict Heart Attacks
March 31, 2022 – Investigators from Cedars-Sinai have created an artificial intelligence-enabled tool that may make it…
Read More
DiA Imaging Analysis Ltd, a leading global provider of AI-powered ultrasound analysis software, announced today a multi-year agreement with Change Healthcare, a global industry-leading provider of enterprise imaging solutions.
March 31, 2022
DiA Imaging Analysis Teams up with Healthcare Technology Company to Expand its AI Offering for Echo-lab Cardiac Exams
March 31, 2022 – DiA Imaging Analysis Ltd, a leading global provider of AI-powered ultrasound analysis software,…
Read More
Windtree Therapeutics, a biotechnology company focused on advancing multiple late-stage interventions for acute cardiovascular and pulmonary disorders, today announced it has successfully completed enrollment in its phase 2 study of istaroxime in early cardiogenic shock caused by heart failure.
March 31, 2022
Windtree Completes Enrollment of Phase 2 Study of Istaroxime in Early Cardiogenic Shock
March 31, 2022 – Windtree Therapeutics, a biotechnology company focused on advancing multiple late-stage interventions…
Read More
Instylla, Inc., a privately held company developing next-generation liquid embolics for peripheral vascular embolotherapy, today announced the publication of results from the first-in-human clinical trial of Embrace Hydrogel Embolic System (HES) for the treatment of hypervascular tumors, in the Journal of Vascular and Interventional Radiology (JVIR).
March 31, 2022
Instylla First-In-Human Clinical Trial Published Results Demonstrate Technical Success and Persistent Embolization Across All Patients
March 31, 2022 – Instylla, Inc., a privately held company developing next-generation liquid embolics for peripheral…
Read More
Vivasure Medical, a company pioneering novel fully absorbable technology for percutaneous vessel closure, today announced that the first patient was treated in a U.S. early feasibility study evaluating PerQseal+, the next generation of the company’s PerQseal device.
March 31, 2022
Vivasure Medical Announces First Patient Treated in U.S. Early Feasibility Study Evaluating PerQseal+
March 31, 2022 – Vivasure Medical, a company pioneering novel fully absorbable technology for percutaneous vessel…
Read More
One in 5 people worldwide have high Lipoprotein(a) – sometimes referred to as “L-P-little a” – an important genetic risk factor for premature heart disease and stroke.
March 31, 2022
The Silent, Undetected Cause of Early Heart Disease
March 31, 2022 – One in 5 people worldwide have high Lipoprotein(a) – sometimes referred to as “L-P-little a” – an…
Read More
University Hospitals Cleveland Medical Center
March 31, 2022
Study Shows Link Between Socioeconomic Deprivation and Premature Cardiovascular Mortality
March 31, 2022 – People living in socially-deprived areas of the United States are more likely to die prematurely from…
Read More
A study conducted at São Paulo State University (UNESP) in Brazil shows that even mild to moderate infection by SARS-CoV-2 can cause an imbalance in the cardiovascular system of young adults without pre-existing diseases.
March 31, 2022
Study: Even Mild or Moderate COVID-19 Can Affect the Cardiovascular System in Young Adults
 March 31, 2022 – A study conducted at São Paulo State University (UNESP) in Brazil shows that even mild to moderate…
Read More
Clinician-scientists in the Smidt Heart Institute at Cedars-Sinai developed a clinical algorithm that, for the first time, distinguishes between treatable sudden cardiac arrest and untreatable forms of the condition. 
March 30, 2022
Cedars-Sinai Researchers Are the First to Distinguish Between Treatable and Untreatable Sudden Cardiac Arrest
March 30, 2022 — Clinician-scientists in the Smidt Heart Institute at Cedars-Sinai developed a clinical algorithm that…
Read More
CT scanner
March 29, 2022
CCT Offers a Safer Alternative to Cardiac Catheterization in CAD Diagnosis
March 29, 2022 – Cardiac computed tomography (CCT) is an accurate, noninvasive diagnostic test for obstructive coronary…
Read More
Artio Medical, Inc., a medical device company developing innovative products for the peripheral vascular, neurovascular, and cardiology markets, has received US Food and Drug Administration (FDA) clearance for its Solus Gold Embolization Device, a next-generation product for peripheral vascular occlusion.
March 29, 2022
Artio Medical Receives FDA Clearance for Solus Gold Embolization Device
March 29, 2022 – Artio Medical, Inc., a medical device company developing innovative products for the peripheral…
Read More
Eko, a digital health company advancing heart and lung disease detection, has announced the launch of its newly-redesigned Eko App, which will transform patient interactions into an opportunity to screen for cardiovascular disease.
March 29, 2022
Eko Launches Screening Solution to Help Catch Heart Disease Early
March 29, 2022 – Eko, a digital health company advancing heart and lung disease detection, has announced the launch of…
Read More
Impulse Dynamics, a company dedicated to innovative treatments for chronic heart failure, has successfully completed the requirements for certification of its quality management system (QMS) under the new Medical Device Regulation (MDR) (EU 2017/745 ) now in force in the European Union (EU).
March 29, 2022
Impulse Dynamics' Quality Management System Receives Certification Under European Union Medical Device Regulation
March 29, 2022 – Impulse Dynamics, a company dedicated to innovative treatments for chronic heart failure, has…
Read More
Today the U.S. Food and Drug Administration (FDA) and the Centers for Disease Control and Prevention (CDC) approved the use of a second COVID-19 booster shot for adults over age 50 and certain immunocompromised individuals, including heart transplant patients.
March 29, 2022
Second Booster Approved as Option for Additional Protection Against COVID-19
March 29, 2022 — Today the U.S. Food and Drug Administration (FDA) and the Centers for Disease Control and Prevention (…
Read More
HeartPoint Global, a leading medical device company dedicated to providing high-quality, minimally invasive cardiac care globally, announced another major milestone in the ongoing pre-clinical trials of the HeartPoint Global Implant System (HPGS), a first-of-its-kind patented, adjustable system which focuses on treating devastating left heart diseases, congestive heart failure, and structural pulmonary hypertension.
March 28, 2022
HeartPoint Global's Implant System Proves Safety and Efficacy
March 28, 2022 — HeartPoint Global, a leading medical device company dedicated to providing high-quality, minimally…
Read More
Aeson total artificial heart showing Open view with pumps and electronics (blue), blood chambers (maroon) and conduits (top, white). Image courtesy of Carmat.
March 28, 2022
Carmat Announces the Restart of Production
March 28, 2022 — Carmat, the designer and developer of the world’s most advanced total artificial heart, aiming to…
Read More
In the first study to examine differences by sex and race in outcomes following the seven most common procedures for heart problems, researchers found that women are less likely to undergo these procedures—and even when women do receive these procedures, they are more likely than men to die while in the hospital, according to data that will be presented at the American College of Cardiology’s 71st Annual Scientific Session.
March 25, 2022
Women Less Likely to Receive Life-saving Heart Procedures
March 25, 2022 – In the first study to examine differences by sex and race in outcomes following the seven most common…
Read More
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now